Business Wire

Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations

Control-IQ technology also offers optional settings for sleep and exercise that will change treatment values to better match the different physiologic needs during these activities. About Tandem ...
Business Wire

Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of ...
Nasdaq

Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Hosted on MSN

FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
The American Journal of Managed Care

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Nasdaq

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin ...